Unicycive Therapeutics, Inc.

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for …

Biotechnology

US, Los Altos [HQ]

Summary
IR
Fin. Reports
Financials
Leadership & Strategy
Possible Catalysts

Analysts
Dividend Payments
Government Awards
Insiders
Lobbying Expenses
Segment Revenues
Shareholder Structure
Supply / Portfolio
Valuation Models [Soon]

Lobbying Analysis

Lobbying · US Senate · Influence

Here you'll find all expenses made over the past 12M of Unicycive Therapeutics, Inc. to fulfill lobbying activities in the US.

Unicycive Therapeutics, Inc. has no lobbying expenses in our database.

History

Download

FY	Quarter	Expense For Lobby Disclosure	LDA Reference
No data